Friday, June 18, 2021
Home BNOW BOON Engages DiOx+ Broad-Spectrum Applications While Finalizing $52M Contract

BOON Engages DiOx+ Broad-Spectrum Applications While Finalizing $52M Contract

SACRAMENTO, CA, Jan. 28, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — BOON Industries (OTC PINK:BNOW) (“BOON” or the “Company”), announces while the company is finalizing the distribution details for their contract worth $52M per year in revenue, it prepares to receive purchase orders for hospital based applications for an additional projected $12M annual revenue.

Justin Gonzalez, CEO, stated, “Our proprietary DiOx+ product offers an activated Chlorine Dioxide (ClO2) broad spectrum disinfectant that kills harmful organisms within seconds with no residual toxicity. DiOx+ has applications in the food safety, healthcare, hospitality, transportation, and water treatment industries. Chlorine dioxide (ClO2) technology protects the environment and human health from dangerous bacteria and harmful by-products formed by other disinfection methods. For example, in the pulp and paper industry, the use of ClO2 has virtually eliminated dioxin in mill wastewater and has led to significant improvements in surrounding ecosystems. As a result, the Federal government is phasing out the use of chlorine in pulp mills over the next few years.”

Mr. Gonzalez further stated, “Our sales team is engaged with several hospital contracts and we anticipate immediate additional revenue streams of $12M per year. Boon will be part of the $6.5B healthcare disinfectant market. DiOx+ is a water-based formula and not an alcohol based product. Although the alcohol-based segment is likely to grow at the highest CAGR of over 12% during 2020–2026 as ethanol, IPA alcohols can be highly effective for killing microbes, viruses, and bacteria in the short term, this market is highly saturated. Our DiOx+ product is five hundred thousand times more oxidative than alcohol and more suitable to effectively manage the most resistant of germs. The liquid-based segment for our DiOx+ is projected to reach a revenue figure of close to $8 billion by 2026 as most commercial medical-grade disinfectants are in the liquid form. The U.S. disinfectant market is expected to reach over $5 billion by 2026 due to the prevalence of HAIs and the rise in acute and chronic diseases.”

VISIT WWW.DIOXPLUS.COM

Safe Harbor for Forward-Looking Statements: This news release contains forward-looking statements which are not statements of historical fact. Forward-looking statements include estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to changes in general economic and financial market conditions. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Contact:

Boon Industries, Inc.

www.boonindustries.com

Investor Relations
530-648-1333
admin@boonindustries.com


Disclaimer

This article is for the purposes of solicitation subscriptions for this website. This website expects to generate new advertisement revenue resulting from the distribution of this article. The amount of which is unknown at this time. This website or it’s authors do not own any shares of Boon Industries Inc (BNOW) and does not buy, sell, or trade any shares of (BNOW). This article does not provide a professional analysis of a (BNOW) financial position. (BNOW) financial position and all other information regarding the featured Company should be verified directly with (BNOW). Please read our full disclaimer for more detailed information.

Most Popular

NxGen Brands, Inc. Enters Into A Definitive Agreement To Acquire 100% Of Healthcard LLC; Acquisition Brings Company Ownership Of Proprietary Patent Pending Patient Centric...

NxGen Brands, Inc. Enters Into A Definitive Agreement To Acquire 100% Of Healthcard LLC; Acquisition Brings Company Ownership Of Proprietary Patent Pending Patient...

NxGen Brands, Signs Letter of Intent (LOI) to Acquire HealthCard, Technology Company That Has Patent Pending Registration for Patient Centric Universal Health Recording &...

NxGen Brands, Signs Letter of Intent (LOI) to Acquire HealthCard, Technology Company That Has Patent Pending Registration for Patient Centric Universal Health Recording...

Nutra Pharma Announces that Diverse Health Services has Added Nyloxin to Their Product Offerings

Diverse Health Services, an industry leader in Chiropractic care and Alternative Medicine, announced the addition of the Nyloxin(R) line of pain relief...

Nutra Pharma Announces Private Label Expansion of their Over-The-Counter Pain Relievers

Nutra Pharma is announcing the first private label agreement in expansion of their line of over-the-counter pain relievers and anti-inflammatory drugs

Advertisement

Subscribe to our Stock News Alerts

Mobile is not required however if you want the fastest
delivery be sure to add your mobile.

Subscribe to our News Alerts
Loading